People Science, a provider of an end-to-end decentralized clinical trial management app that allows researchers to study alternative medicines and wellness interventions at scale, raised $5.3 million in a second round of seed funding.
Acre Venture Partners led the investment round with participation from Bluestein Ventures, THIA Ventures, and FORM Life Ventures.
According to the press release, this latest funding round brings the company’s total seed funding to date to $8.5 million. Noetic Fund, Woven Science, and LifeForce Capital led the company’s previous seed round.
According to the company website, People Science has been building a new clinical research infrastructure for alternative medicines that connects people, doctors, and scientists through its technology platform, CHLOE (the Consumer Health Learning and Organizing Ecosystem).
CHLOE is a modular software technology that combines a consumer-facing mobile app with a high-quality clinical research platform. Consumers can use CHLOE to help understand which alternative medicines work best for themselves. Companies and other researchers engage with People Science to test their ideas and products directly or by licensing CHLOE. Sponsored clinical studies with CHLOE began in late 2022, with the goal of launching the app to the public in early 2023.
With the latest funds, People Science will continue to develop the CHLOE technology platform to support additional consumer-facing features as well as to support their growing client pipeline for CHLOE software licensing. The core team will expand to support customer growth and retention.
Commenting on the funding news, Belinda Tan, co-founder and co-CEO of People Science, said: “We’re seeking to advance and validate knowledge about alternative medicines.” “By sharing and creating tremendously valuable evidence through the use of our technology and including people from all backgrounds, we’re building bridges between our modern society and indigenous cultures. Humans have the power to improve themselves and we are providing them with better tools to do so.”
Clinical trial startups
According to our database, decentralized clinical trial management software startups have raised close to $2 billion in funding to date.
The latest funding rounds in the clinical trial tech space include.
Quris.ai, an artificial intelligence platform that predicts which drug candidates will safely work in humans, raised an additional $9 million in seed funding led by SoftBank Vision Fund 2, with participation from existing investors GlenRock Capital, iAngels, Welltech Ventures, and Richter Group.
Vial, a provider of an end-to-end online clinical trials management platform for biotech companies, raised $67 million in Series B funding led by General Catalyst with participation from Byers Capital, BoxGroup, and other investors.
